<a href="https://laohu8.com/S/LIXT">Lixte Biotechnology Holdings Inc.</a> Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> Synergies
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) has announced the continuation of its clinical programs involving LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, designed to enhance cancer treatment. LB-100 is currently being evaluated in collaboration with pharmaceutical partners in various cancer studies. These include a trial for ovarian clear-cell carcinoma in partnership with GSK, which is providing Dostarlimab and supporting full trial funding. Additionally, LB-100 is being assessed for MSS colorectal cancer in collaboration with Roche at the Netherlands Cancer Institute, although this study is currently under a temporary voluntary safety pause due to early adverse events. The results of these trials have not yet been presented, as the studies are ongoing. Lixte aims to validate LB-100's safety and efficacy and explore its potential to improve the effectiveness of existing cancer therapies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 265118) on September 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。